anastrozole has been researched along with Bone Diseases, Metabolic in 9 studies
Bone Diseases, Metabolic: Diseases that affect the METABOLIC PROCESSES of BONE TISSUE.
Excerpt | Relevance | Reference |
---|---|---|
"Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures." | 9.30 | Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. ( Blake, GM; Coleman, RE; Cuzick, J; Eastell, R; Patel, R; Sestak, I, 2019) |
"6 mg subcutaneously every 28 days), both with or without zoledronic acid (4 mg intravenously every 6 months) for 3 years in premenopausal women with endocrine-responsive breast cancer." | 9.13 | Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. ( Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P, 2008) |
"In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 5.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
"Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures." | 5.30 | Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. ( Blake, GM; Coleman, RE; Cuzick, J; Eastell, R; Patel, R; Sestak, I, 2019) |
"6 mg subcutaneously every 28 days), both with or without zoledronic acid (4 mg intravenously every 6 months) for 3 years in premenopausal women with endocrine-responsive breast cancer." | 5.13 | Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. ( Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P, 2008) |
"Drugs used to treat cancer may affect the skeleton in several ways, the most important being a decrease in sex steroid levels." | 2.44 | Skeletal effects of drugs to treat cancer. ( Vestergaard, P, 2008) |
"In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 1.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
"University of Colorado Cancer Center breast cancer patients treated with aromatase inhibitor therapy during July 2005 through July 2006 were studied." | 1.35 | Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors. ( Gibson, K; O'Bryant, CL, 2008) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (44.44) | 29.6817 |
2010's | 5 (55.56) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Livi, L | 1 |
Scotti, V | 1 |
Desideri, I | 1 |
Saieva, C | 1 |
Cecchini, S | 1 |
Francolini, G | 1 |
Becherini, C | 1 |
Delli Paoli, C | 1 |
Visani, L | 1 |
Salvestrini, V | 1 |
De Feo, ML | 1 |
Nori, J | 1 |
Bernini, M | 1 |
Sanchez, L | 1 |
Orzalesi, L | 1 |
Bianchi, S | 1 |
Meattini, I | 1 |
Sestak, I | 1 |
Blake, GM | 1 |
Patel, R | 1 |
Coleman, RE | 1 |
Cuzick, J | 1 |
Eastell, R | 1 |
Vestergaard, P | 1 |
Gnant, M | 1 |
Mlineritsch, B | 1 |
Luschin-Ebengreuth, G | 1 |
Kainberger, F | 1 |
Kässmann, H | 1 |
Piswanger-Sölkner, JC | 1 |
Seifert, M | 1 |
Ploner, F | 1 |
Menzel, C | 1 |
Dubsky, P | 1 |
Fitzal, F | 1 |
Bjelic-Radisic, V | 1 |
Steger, G | 1 |
Greil, R | 1 |
Marth, C | 1 |
Kubista, E | 1 |
Samonigg, H | 1 |
Wohlmuth, P | 1 |
Mittlböck, M | 1 |
Jakesz, R | 1 |
Gibson, K | 1 |
O'Bryant, CL | 1 |
Geisler, J | 1 |
Lønning, PE | 1 |
Markopoulos, C | 2 |
Tzoracoleftherakis, E | 1 |
Koukouras, D | 1 |
Venizelos, B | 1 |
Zobolas, V | 1 |
Misitzis, J | 1 |
Xepapadakis, G | 1 |
Gogas, H | 1 |
Denes, AE | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Single--blind, Randomized, Placebo--controlled Phase II Study to Evaluate the Impact of Oral Bisphosphonate Treatment on Bone Mineral Density in Osteopenic Women Receiving Adjuvant Aromatase Inhibitors - BONADIUV Trial[NCT02616744] | Phase 2 | 171 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid, in Premenopausal, Hormone Receptor-positive Breast Cancer Patients (Stage I, II)[NCT00295646] | Phase 3 | 1,803 participants (Actual) | Interventional | 1999-06-30 | Completed | ||
A Multicenter, Single-arm, Phase II Study to Evaluate the Activity of Pre-operative Zoledronate in Triple Negative Breast Cancer Patients, According to p53 Level[NCT02347163] | Phase 2 | 22 participants (Actual) | Interventional | 2015-02-03 | Terminated (stopped due to The study stopped prematurely due to the low accrual rate) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for anastrozole and Bone Diseases, Metabolic
Article | Year |
---|---|
Skeletal effects of drugs to treat cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Diseases, Meta | 2008 |
3 trials available for anastrozole and Bone Diseases, Metabolic
5 other studies available for anastrozole and Bone Diseases, Metabolic
Article | Year |
---|---|
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic | 2008 |
Impact of aromatase inhibitors on bone health in breast cancer patients.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone and Bones; | 2010 |
Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.
Topics: Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Me | 2010 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Densit | 2012 |
Case 24-2005: a woman with estrogen-receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Diseases, Metabolic; Breast Neoplasms; Chemothera | 2005 |